Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?. (6th February 2015)
- Record Type:
- Journal Article
- Title:
- Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?. (6th February 2015)
- Main Title:
- Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
- Authors:
- Nipp, Ryan D.
Ryan, David P. - Abstract:
- Abstract : The TRIBE trial compared the FOLFOXIRI regimen plus bevacizumab with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. FOLFOXIRI plus bevacizumab is an acceptable therapeutic option, but the results of the TRIBE trial do not establish this regimen as the best treatment option for patients with metastatic colorectal cancer.
- Is Part Of:
- Oncologist. Volume 20:Number 3(2015)
- Journal:
- Oncologist
- Issue:
- Volume 20:Number 3(2015)
- Issue Display:
- Volume 20, Issue 3 (2015)
- Year:
- 2015
- Volume:
- 20
- Issue:
- 3
- Issue Sort Value:
- 2015-0020-0003-0000
- Page Start:
- 236
- Page End:
- 238
- Publication Date:
- 2015-02-06
- Subjects:
- Oncology -- Periodicals
Tumors -- Periodicals
Cancérologie -- Périodiques
Tumeurs -- Périodiques
Oncology
Tumors
Neoplasms
Electronic journals
Periodicals
Periodicals
616.994 - Journal URLs:
- https://academic.oup.com/oncolo ↗
https://theoncologist.onlinelibrary.wiley.com/journal/1549490x ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1634/theoncologist.2014-0495 ↗
- Languages:
- English
- ISSNs:
- 1083-7159
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6256.890000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20723.xml